Author | Kristie L. Kahl | OncLive

Author | Kristie L. Kahl


Updated Findings Show Olaparib Prolongs OS in Men with mCRPC

September 20, 2020

Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

AMG 330 Shows Promise in Treating Relapsed/Refractory AML

May 30, 2020

Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia, with cytokine release syndrome as the most frequent and expected adverse event.

Frontline Nivolumab/Ipilimumab Combo with Limited Chemo Improves OS in NSCLC

May 30, 2020

Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.

Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced NSCLC

May 29, 2020

Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.